DNA Intercalating Near-Infrared Luminescent Lanthanide Complexes Containing Dipyrido[3,2-a:2',3'-c]phenazine (dppz) Ligands: Synthesis, Crystal Structures, Stability, Luminescence Properties and CT-DNA Interaction

In order to create near-infrared (NIR) luminescent lanthanide complexes suitable for DNA-interaction, novel lanthanide dppz complexes with general formula [Ln(NO3)3(dppz)2] (Ln = Nd3+, Er3+ and Yb3+; dppz = dipyrido[3,2-a:2',3'-c]phenazine) were synthesized, characterized and their luminescence properties were investigated. In addition, analogous compounds with other lanthanide ions (Ln = Ce3+, Pr3+, Sm3+, Eu3+, Tb3+, Dy3+, Ho3+, Tm3+, Lu3+) were prepared. All complexes were characterized by IR spectroscopy and elemental analysis. Single-crystal X-ray diffraction analysis of the complexes (Ln = La3+, Ce3+, Pr3+, Nd3+, Eu3+, Er3+, Yb3+, Lu3+) showed that the lanthanide's first coordination sphere can be described as a bicapped dodecahedron, made up of two bidentate dppz ligands and three bidentate-coordinating nitrate anions. Efficient energy transfer was observed from the dppz ligand to the lanthanide ion (Nd3+, Er3+ and Yb3+), while relatively high luminescence lifetimes were detected for these complexes. In their excitation spectra, the maximum of the strong broad band is located at around 385 nm and this wavelength was further used for excitation of the chosen complexes. In their emission spectra, the following characteristic NIR emission peaks were observed: for a) Nd3+: 4F3/2 → 4I9/2 (870.8 nm), 4F3/2 → 4I11/2 (1052.7 nm) and 4F3/2 → 4I13/2 (1334.5 nm); b) Er3+: 4I13/2 → 4I15/2 (1529.0 nm) c) Yb3+: 2F5/2 → 2F7/2 (977.6 nm). While its low triplet energy level is ideally suited for efficient sensitization of Nd3+ and Er3+, the dppz ligand is considered not favorable as a sensitizer for most of the visible emitting lanthanide ions, due to its low-lying triplet level, which is too low for the accepting levels of most visible emitting lanthanides. Furthermore, the DNA intercalation ability of the [Nd(NO3)3(dppz)2] complex with calf thymus DNA (CT-DNA) was confirmed using fluorescence spectroscopy

Czy możliwe jest wybranie „najlepszego” hipotensyjnego połączenia lekowego?

  Currently, approximately one third of adult Poles suffers from hypertension (HT). Most of current hy­potensive drugs in monotherapy lowers blood pres­sure values of less than 20/10 mm Hg. In most of the patients, this reduction is not sufficient. That is way, more and more is said about the use of hypotensive drugs consisting of several components, because due to their complimentary actions, the effectiveness of antihypertensive treatment is increased and better doctor-patient collaboration and treatment adherence is assured. The article presents clinical aspects of the use of telmisartan (“the best” angiotensin receptor blocker) with amlodipine, widely used calcium chan­nel antagonist.Około 1/3 dorosłych Polaków choruje na nadciśnienie tętnicze (HT). Większość współczesnych leków hipotensyjnych stosowanych pojedynczo wykazuje efekt hipotensyjny związany z redukcją wartości ciśnienia tętniczego w zakresie znacznie mniejszym niż 20/10 mmHg. U wielu pacjentów nie jest to redukcja wystarczająca. Dlatego też, coraz więcej mówi się o stosowaniu preparatów wieloskładnikowych, które dzięki wzajemnie uzupełniającemu się działaniu zawartych w nich substancji oraz pozytywnym wpływie na współpracę na linii lekarz — pacjent zwiększają skuteczność leczenia hipotensyjnego. W artykule przedstawiono kliniczne aspekty stosowania preparatu złożonego z telmisartanu, można powiedzieć „najlepszego” z sartanów, z amlodipiną, powszechnie stosowanym antagonistą wapnia

Peripheral nerve involvement in myotonic dystrophy type 2 – similar or different than in myotonic dystrophy type 1?

Introduction Multisystem manifestations of myotonic dystrophies type 1 (DM1) and 2 (DM2) are well known. Peripheral nerve involvement has been reported in DM1 but not in genetically confirmed DM2. The aim of our study was to assess peripheral nerve involvement in DM2 using nerve conduction studies and to compare these results with findings in DM1. Methods We prospectively studied patients with genetically confirmed DM2 (n=30) and DM1 (n=32). All patients underwent detailed neurological examination and nerve conduction studies. Results Abnormalities in electrophysiological studies were found in 26.67% of patients with DM2 and in 28.13% of patients with DM1 but the criteria of polyneuropathy were fulfilled in only 13.33% of patients with DM2 and 12.5% of patients with DM1. The polyneuropathy was subclinical, and no correlation was found between its presence and patient age or disease duration. Conclusions Peripheral nerves are quite frequently involved in DM2, but abnormalities meeting the criteria of polyneuropathy are rarely found. The incidence of peripheral nerve involvement is similar in both types of myotonic dystrophy

Supplementary data for article: Van Deun, R.; D’Hooge, M.; Savic, A.; Van Driessche, I.; Van Hecke, K.; Kaczmarek, A. M. Influence of Y3+, Gd3+, and Lu3+ Co-Doping on the Phase and Luminescence Properties of Monoclinic Eu:LaVO4 Particles. Dalton Transactions 2015, 44 (42), 18418–18426. https://doi.org/10.1039/c5dt03147h

Supplementary material for: [https://doi.org/10.1039/c5dt03147h]Related to published version: [http://cherry.chem.bg.ac.rs/handle/123456789/1988]Related to accepted version: [http://cherry.chem.bg.ac.rs/handle/123456789/3379

Luminescence of Ce3+ multicenters in Ca2+ -Mg2+ -Si4+ based garnet phosphors

Comparison of the luminescent properties of Ca3Sc2Si3O12: Ce and Ca2YMgScSi3O12: Ce single crystalline films (SCF) phosphors, grown by the liquid phase epitaxy method, was performed in this work. We have observed formation of the Ce3+ multicenters in Ca3Sc2Si3O12: Ce and Ca2YMgScSi3O12: Ce in the emission and excitation spectra as well as in the decay kinetics of the Ce3+ luminescence in SCFs of these garnets. Such Ce3+ multicenters possess different crystal field strength due to the inhomogeneous local surroundings of the dodecahedral positions of garnet host at the substitution of the octahedral positions by hetero-valence Mg2+ and Sc3+ ions and the tetrahedral positions by Si4+ ions. We confirm the presence of an effective energy transfer between different Ce3+ multicenters in Ce3+ doped Ca3Sc2Si3O12 and Ca2YMgScSi3O12 garnets. The positive trends in variations of the spectroscopic properties of the Ca2YMgScSi3O12: Ce garnet with respect to Ca3Sc2Si3O12: Ce garnet were observed also due to substitution of the dodecahedral sites of the garnet host by Y3+ ions and the octahedral sites by Mg2+ ions, which can be suitable for the development of new converters of white LEDs. Namely, due to the Y3+-Mg2+ doping, the luminescence spectrum of Ce3+ ions in Ca2YMgScSi3O12: Ce SCFs significantly extends in the red range in comparison with the Ca3Sc2Si3O12: Ce SCF counterpart

Antitumor activity of organoruthenium complexes with chelate aromatic ligands, derived from 1,10-phenantroline: Synthesis and biological activity

The monocationic chloro complexes containing chelating N∩N ligands: [(η6-p-cymene)Ru(L1–4)Cl]+ (1–4), where L1 = 4-methyl-1,10-phenantroline, L2 = dipyrido[3,2-a:2′,3′-c]phenazine, L3 = 11-chloro-dipyrido[3,2-a:2′,3′-c]phenazine, L4 = 11-nitro-dipyrido[3,2-a:2′,3′-c]phenazine; p-cymene = 1-methyl-4-isopropylbenzene) have been prepared and characterized as the hexafluorophosphate salts. The biological activity of 1–4 has been investigated in selected 2D monolayer cell cultures (A549, PANC-1, MDA-MB-231, MRC-5). All investigated ruthenium complexes showed similar or even better cytotoxicity to cisplatin. However, there was no significant reduction in growth of PANC-1 cells in a 3D cell culture of multicellular tumor spheroids (MCTS) after treatment with 2–4, while the cisplatin treatment induced retardation in MCTS growth. Flow cytometry analysis of the cell cycle of PANC-1 cells shows that 3 caused changes of cell cycle phase distribution characterized by slight accumulation of cells in the G2-M phase. Absence of the Sub-G1 phase in the cell cycle of the treated cells indicated that there was no fragmentation of DNA for the analyzed time intervals (48 and 72 h treatment). Fluorescent microscopy, after acridine orange/ethidium bromide staining, revealed that the investigated ruthenium complexes induced some characteristics of apoptotic morphology (shrinking and condensation of chromatin) with notably preserved integrity of the plasma membrane. Investigation of cellular uptake and DNA - fraction accumulation performed by inductively coupled plasma mass spectrometry in PANC-1 cells with equimolar concentrations (5 μM) of 2–4 and cisplatin showed more efficient cellular uptake and DNA - fraction accumulation of complex 3 compared to complexes 2 and 4

Związek układu serotoninergicznego i układu sercowo-naczyniowego

Serotonin plays an important role in regulating the cardiovascular system. Drugs widely used in the treatment of depression, migraine, Parkinson’s disease or obesity affect the serotonergic system. The use of these compounds causes both acute and chronic effects, depending on the type of activated 5-HT receptor and its location. An acute cardiac response to 5-HT, known as Bezold-Jarisch reflex, leads to bradycardia and hypotension. The chronic contribution of serotonin may be associated with fibrosis and cardiac valve degeneration. This article analyses the impact of 5-HT receptors activation on the cardiovascular system and describes side effects of this activation and new therapies targeting this system.Serotonina (5-HT) odgrywa istotną rolę w regulacji układu sercowo-naczyniowego. Leki wpływające na układ serotoninergiczny powszechnie stosuje się w terapii depresji, migreny, choroby Parkinsona czy otyłości. W zależności od rodzaju aktywowanego receptora 5-HT i jego lokalizacji przyjmowanie tych związków może prowadzić do ostrych i przewlekłych skutków. Przykładem takiego oddziaływania jest ostra odpowiedź kardiologiczna na serotoninę, zwana odruchem Bezolda-Jarisha, która prowadzi do bradykardii i hipotonii. Przewlekła ekspozycja na nadmiar serotoniny może natomiast łączyć się z włóknieniem i zwyrodnieniem zastawek serca. W artykule omówiono wpływ aktywacji poszczególnychreceptorów 5-HT na układ sercowo-naczyniowy, działania niepożądane stosowanych leków, a także wskazano nowemożliwości terapii

Risk factors and potential outcomes of COVID-2019 — a narrative review with focus on cardiovascular health

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), spreads rapidly and has been announced a pandemic by the World Health Organization (WHO). COVID-19 especially affects cardiovascular system, mostly by leading to the dysfunction of endothelium and its consequences. On the other hand, patients with a history of chronic disease are believed to have a more severe course of COVID-19. Furthermore, apart from an undoubted influence on morbidity and mortality, COVID-19 results in changes in many aspects of human life. It is worth noting that pandemic will also affect people who did not suffer from disease. Nevertheless, due to constantly elevated stress level, COVID-19 may have influence on mental health. Paradoxically, in dealing with stress and COVID-related problems, faith and religiosity can play a leading role. In this review, attention was paid not only to possible cardiac complications of infection but also to the impact of the pandemic on psychological and spiritual effects of the pandemic.

Zespół kruchości w gabinecie lekarza praktyka — o czym należy pamiętać?

Nie u wszystkich pacjentów proces starzenia się przebiega w ten sam sposób. Tempo postępowania tego procesu, zarówno fizycznego, jak i psychicznego, jest bardzo różne. Jakość życia pacjenta w podeszłym wieku zależy od bardzo wielu czynników, w tym stylu życia, predyspozycji genetycznych oraz odpowiedniej opieki medycznej. Jakość opieki zdrowotnejzależy między innymi od tego, jak szybko i czy prawidłowo lekarz dostrzeże u pacjenta oznaki przedwczesnego, czy „nieprawidłowego” starzenia się. Aby to ułatwić, wyodrębniono zespół objawów, których występowanie powinno zaalarmować lekarza ze względu na związek ze zwiększoną śmiertelnością. W piśmiennictwie anglojęzycznym zespół ten nosi nazwę frailty syndrome. W piśmiennictwie polskim najszerzej używane określenie tego zjawiska to prawdopodobnie „zespół kruchości”. Celem niniejszego opracowania było przedstawienie znaczenia tego zespołu w praktyce klinicznej